Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

La Raza Medical Center

Status and phase: Completed; Phase 2; Phase 1

Conditions: Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma

Treatments: Drug: Filgrastim 0.3 MG/ML; Drug: Dexamethasone; Drug: Carboplatin; Drug: Rituximab; Drug: Cytarabine Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT03892421

R-2018-3501-014

Details and patient eligibility

About

The goal of this study is to evaluate the efficacy and safety of a combination of the anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and Carboplatin; delivered in an outpatient setting.

Full description

The R-DHAP (Rituximab, Dexamethasone, Cytarabine, and Cisplatin) schedule includes high-dose cytarabine every 12 hours and requires careful monitoring of renal toxicity because of cisplatin. These conditions limit the use of this protocol in an outpatient setting.

The S phase of lymphoma cells is longer than 12 hours, then cytarabine can be used daily without reduction of the antineoplastic effect. Carboplatin does not have remarkable renal toxicity so is not necessary to monitor blood chemistry or IV fluids during its administration.

The study hypothesis is that modifications to the original R-DHAP protocol, using cytarabine on a daily basis and the substitution of cisplatin by carboplatin can preserve the efficacy, reducing the incidence of renal events. The investigators hypothesize that those modifications can make the schedule more suitable for an outpatient administration in relapsed or refractory non-Hodgkin lymphoma patients.

After 3 cycles of chemotherapy, the overall response and the incidence of adverse events will be evaluated.

In order to achieve the purpose of this trial, 130 participants will be included.

Enrollment: 22 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of recurrent or refractory B-cell non-Hodgkin lymphoma
• Performance status: Eastern Cooperative Oncology Group 0-2
• At least three weeks from last chemotherapy
• Toxicities by Common Terminology Criteria Version 4.0 ≤ 1
• Glomerular filtration rate >50 ml/min
• Women of childbearing potential must use effective methods of contraception

Exclusion criteria

• Post-transplant relapse of lymphoma
• Central nervous system involvement of lymphoma
• Serious infections
• Known allergies to one or more of the experimental drugs
• Diabetes with glucose >200 mg/dl
• Pregnant or lactating females
• Known HIV or B Hepatitis positivity
• Known allergies to filgrastim

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Modified DHAP

Experimental group

Description:

Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.

Treatment:

Drug: Dexamethasone

Drug: Rituximab

Drug: Carboplatin

Drug: Filgrastim 0.3 MG/ML

Drug: Cytarabine Injection